Sarepta Therapeutics (MEX:SRPT) Inventory Turnover: 0.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN294.00
GF Value MXN2,154.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Inventory Turnover?

Sarepta Therapeutics MEX:SRPT 36 Inventory Turnover is 0.11 as of Mar. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,154.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Sarepta Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was MXN1,961 Mil. Sarepta Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was MXN17,262 Mil. Sarepta Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.11.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sarepta Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 803.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sarepta Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.31.

Sarepta Therapeutics  (MEX:SRPT) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sarepta Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=17261.679/1961.38*365 / 4
=803.07

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sarepta Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=17261.679 / 13178.351
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Sarepta Therapeutics Inventory Turnover Related Terms

Sarepta Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Inventory Turnover Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.70 0.54 0.63 0.94

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.15 0.14 0.40 0.11
MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Inventory Turnover Calculation

Sarepta Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=15117.676 / ((15640.941 + 16470.606) / 2 )
=15117.676 / 16055.7735
=0.94

Sarepta Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=1961.38 / ((16470.606 + 18052.752) / 2 )
=1961.38 / 17261.679
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.11 mean?
Sarepta Therapeutics (MEX:SRPT) has a Inventory Turnover of 0.11 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Inventory Turnover too high?
Sarepta Therapeutics' current Inventory Turnover is 0.11. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Inventory Turnover compare to ZYME and BCAX?
Sarepta Therapeutics' Inventory Turnover of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Inventory Turnover is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,154.20, compared to a current price of MXN294.00 — trading 86.4% below its estimated fair value. The current Inventory Turnover is 0.11. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Inventory Turnover is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 86.4% below its estimated GF Value™ of MXN2,154.20. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Inventory Turnover: 0.11
  • GF Value™: MXN2,154.20 vs. price of MXN294.00 (86.4% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,154.20
GF Value